Lindbrook Capital’s Arcturus Therapeutics ARCT Stock Holding History

Lindbrook Capital’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$911	Buy	+86	New	+$1.36K	﹤0.01%	2488
2024 Q4	–	Sell	-144	Closed	-$3.34K	–	2781
2024 Q3	$3.34K	Buy	144 +76	+112%	+$1.63K	﹤0.01%	2171
2024 Q2	$1.66K	Hold	68	–	–	﹤0.01%	2400
2024 Q1	$2.3K	Hold	68	–	–	﹤0.01%	2192
2023 Q4	$2.14K	Buy	+68	New	+$1.62K	﹤0.01%	2231
2022 Q4	–	Sell	-15	Closed	–	–	2832
2022 Q3	$0	Buy	15 +1	+7%	+$17	﹤0.01%	2610
2022 Q2	$0	Buy	+14	New	+$275	﹤0.01%	2475

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Lindbrook Capital's ARCT Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Arcturus Therapeutics (ARCT) in Q1 2025: 86 shares worth $911. The stake represents ﹤0.01% of the portfolio and ranks #2488 among its holdings. This is a return to the name: Lindbrook Capital previously reported a position in ARCT as recently as Q3 2024.

Lindbrook Capital first reported a position in ARCT in Q2 2022 and has held it in 7 quarters since. The position peaked at $3.34K in Q3 2024. 144 funds tracked by Wall St. Rank hold ARCT as of Q1 2025.

Lindbrook Capital held 86 shares of Arcturus Therapeutics worth $911 as of Q1 2025.
Arcturus Therapeutics was a new Lindbrook Capital position in Q1 2025.
Arcturus Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2488 holding.
Lindbrook Capital first reported a position in Arcturus Therapeutics in Q2 2022 and has held it in 7 quarters since.
Lindbrook Capital's Arcturus Therapeutics position peaked at $3.34K in Q3 2024.
144 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.